Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus ERYTHROMYCIN ESTOLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus ERYTHROMYCIN ESTOLATE.
ERYTHROCIN STEARATE vs ERYTHROMYCIN ESTOLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
250-500 mg orally every 6-12 hours
None Documented
None Documented
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic